Payments Review For French Pharmacists

25 May 1997

Just days before the French elections, the government has decided tomeet pharmacists halfway over their demand for a payment review. The current degressive margin system will not be abandoned immediately, but Social Affairs Minister Jacques Barrot has agreed to move now to improve margins.

Under the present system, the dearer a drug, the lower the pharmacist's margin. Mr Barrot says he will reduce the degressive character of the system by cutting the number of graduations from six to three, and leaving a range in the center covering 90% of products - those sold by makers at 10-200 French francs ($1.73-$34.62).

Pharmacy federation president Bernard Capdeville says this means pharmacists' margins, which had been falling 0.5% a year for the last six years, would now drop only 0.2% a year. He sees the move as a first step in reforming the system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight